Cargando…
Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially avail...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724693/ https://www.ncbi.nlm.nih.gov/pubmed/36540243 http://dx.doi.org/10.1039/d2ra06841a |
_version_ | 1784844469568274432 |
---|---|
author | Hu, Wei Zhang, Xiang Liu, Yuanchang Liu, Teng Wen, Jiale Peng, Xiaopeng Xie, Xin Chen, Weiming |
author_facet | Hu, Wei Zhang, Xiang Liu, Yuanchang Liu, Teng Wen, Jiale Peng, Xiaopeng Xie, Xin Chen, Weiming |
author_sort | Hu, Wei |
collection | PubMed |
description | Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially available chloroacetamide in a 72% yield. Then, the key triazone-triazole intermediate was obtained in a second one-pot process by N-alkylation with triazone followed by highly selective N(1)-methylation with iodomethane in a 54% yield. In addition, two of the main process impurities were synthesized and identified. This novel alternative two-stage one-pot strategy for synthesizing the key triazone-triazole intermediate opens a new avenue for further research and development of ensitrelvir analogs. |
format | Online Article Text |
id | pubmed-9724693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-97246932022-12-19 Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 Hu, Wei Zhang, Xiang Liu, Yuanchang Liu, Teng Wen, Jiale Peng, Xiaopeng Xie, Xin Chen, Weiming RSC Adv Chemistry Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially available chloroacetamide in a 72% yield. Then, the key triazone-triazole intermediate was obtained in a second one-pot process by N-alkylation with triazone followed by highly selective N(1)-methylation with iodomethane in a 54% yield. In addition, two of the main process impurities were synthesized and identified. This novel alternative two-stage one-pot strategy for synthesizing the key triazone-triazole intermediate opens a new avenue for further research and development of ensitrelvir analogs. The Royal Society of Chemistry 2022-12-06 /pmc/articles/PMC9724693/ /pubmed/36540243 http://dx.doi.org/10.1039/d2ra06841a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Hu, Wei Zhang, Xiang Liu, Yuanchang Liu, Teng Wen, Jiale Peng, Xiaopeng Xie, Xin Chen, Weiming Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title | Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title_full | Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title_fullStr | Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title_full_unstemmed | Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title_short | Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 |
title_sort | two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (s-217622), an oral clinical candidate for treating covid-19 |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724693/ https://www.ncbi.nlm.nih.gov/pubmed/36540243 http://dx.doi.org/10.1039/d2ra06841a |
work_keys_str_mv | AT huwei twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT zhangxiang twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT liuyuanchang twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT liuteng twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT wenjiale twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT pengxiaopeng twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT xiexin twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 AT chenweiming twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19 |